- ￥1620
- BHcell（博辉生物）
- H-C203
- 2025年12月19日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
【BEAS-2B】BEAS-2B细胞/BEAS-2B细胞/BEAS-2B人支气管上皮细胞Cell line name BEAS-2B
Synonyms Beas-2B; BEAS 2B; BEAS2B; Beas2B; Bronchial Epithelium transformed with Ad12-SV40 2B
Accession CVCL_0168
Resource Identification Initiative To cite this cell line use: BEAS-2B (RRID:CVCL_0168)
Comments Group: Patented cell line.
Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040).
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9609.
Transformant: Ad12-SV40 hybrid virus.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Lung, bronchus, epithelium; UBERON=UBERON_0002031.
Cell type: Epithelial cell of bronchus; CL=CL_0002328.
DOI=10.1007/978-1-4612-0411-4_25
Lehman T.A., Harris C.C.
Neoplastic transformation and suppression of transformation of human bronchial epithelial cells in vitro.
(In book chapter) Neoplastic transformation in human cell system. Mechanism of carcinogenesis; Rhim J.S., Dritschilo A. (eds.); pp.251-258; Humana Press; New York; USA (1990)
PubMed=8504475; DOI=10.1093/carcin/14.5.833
Lehman T.A., Modali R.V., Boukamp P., Stanek J., Bennett W.P., Welsh J.A., Metcalf R.A., Stampfer M.R., Fusenig N.E., Rogan E.M., Harris C.C.
p53 mutations in human immortalized epithelial cell lines.
Carcinogenesis 14:833-839(1993)
PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)
Patent=US5506131
Harris C.C., Gelboin H.V., Gonzalez F.J., Mace K., Pfeifer A.M.A.
Immortalized human cell lines containing exogenous cytochrome P450 genes.
Patent number US5506131, 09-Apr-1996
PubMed=12894236; DOI=10.1038/sj.onc.1206728
Ma Y., Koza-Taylor P.H., DiMattia D.A., Hames L., Fu H.-N., Dragnev K.H., Turi T., Beebe J.S. Jr., Freemantle S.J., Dmitrovsky E.
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.
Oncogene 22:4924-4932(2003)
PubMed=15463957; DOI=10.1016/j.jcf.2004.05.040
Gruenert D.C., Willems M., Cassiman J.-J., Frizzell R.A.
Established cell lines used in cystic fibrosis research.
J. Cyst. Fibros. 3:191-196(2004)
PubMed=17331233; DOI=10.1186/1471-2164-8-62; PMCID=PMC1821332
Nymark P., Lindholm P.M., Korpela M.V., Lahti L., Ruosaari S., Kaski S., Hollmen J., Anttila S., Kinnula V.L., Knuutila S.
Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines.
BMC Genomics 8:62.1-62.14(2007)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22521957; DOI=10.1016/j.taap.2012.04.003; PMCID=PMC3358533
Stueckle T.A., Lu Y.-J., Davis M.E., Wang L.-Y., Jiang B.-H., Holaskova I., Schafer R., Barnett J.B., Rojanasakul Y.
Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells.
Toxicol. Appl. Pharmacol. 261:204-216(2012)
PubMed=25524072; DOI=10.1002/jat.3094; PMCID=PMC4474793
Zhao F., Klimecki W.T.
Culture conditions profoundly impact phenotype in BEAS-2B, a human pulmonary epithelial model.
J. Appl. Toxicol. 35:945-951(2015)
PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)
PubMed=31156620; DOI=10.3389/fimmu.2019.01019; PMCID=PMC6529937
Panda D., Gjinaj E., Bachu M., Squire E., Novatt H., Ozato K., Rabin R.L.
IRF1 maintains optimal constitutive expression of antiviral genes and regulates the early antiviral response.
Front. Immunol. 10:1019.1-1019.16(2019)
PubMed=31900469; DOI=10.1371/journal.pone.0227174; PMCID=PMC6941928
Han X.-Y., Na T., Wu T.-T., Yuan B.-Z.
Human lung epithelial BEAS-2B cells exhibit characteristics of mesenchymal stem cells.
PLoS ONE 15:E0227174-E0227174(2020)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由博辉生物科技（广州）有限公司提供； *发表【英文论文】请标注：From Bohui Biological Technology (Guangzhou) Co., Ltd.
:215595[6] 作者首先通过对 150 个胰腺癌样本分析，发现 HOXB9 表达较高的胰腺癌患者预后较好，然后在细胞系和 PDX 模型中均发现过表达 HOXB9 可以抑制胰腺癌细胞增殖。如下图（图 7）所示，该研究发现了细胞周期和胰腺癌细胞增殖方面一种新的 DNMT1/HOXB9/RBL2/c-Myc 通路调控机制，为胰腺癌预后和治疗提供了新的治疗思路[6]。 图 7：HOXB9 抑制小鼠体内胰腺肿瘤生长[6] B-NDG 小鼠在 TCR-T 细胞治疗中的
批次间稳定一致 重组抗体源于一段只编码一种重链和轻链的DNA序列，从而确保抗体的超高纯度。标准化的培养条件下，由哺乳动物细胞表达，保证了抗体质量的批次间稳定性。 图1：对抗体进行质谱分析，数据表明：REAfinity抗体纯度非常高，而杂交瘤来源的抗体是一种混合物。(A)对两个杂交瘤来源的单克隆抗体样本进行质谱分析，可以看出，它们都含有一条分子量接近23,635Da的污染轻链。(B)两个REAfinity抗体样本的质谱分析结果显示，其含有极高纯度的轻链。 通用型同型
(IF 28) 揭秘黑色素瘤细胞新状态！剑桥大学癌症研究中心最新合作文章揭示强大的基因表达程序是状态转变的基础
，regulon在不同细胞中的活性不同 文章中，基于特定基因，KEGG通路确定10个细胞系的三种状态后，作者利用SCENIC挖掘了影响细胞状态的regulon（图3 a），并构架了对应的GRN（图3 b）。结果表明，melanocytic状态具有高活性的SOX10, TFAP2A, MITF, IRF4, HES6和SOX4，其中SOX10和MITF是黑色素细胞系特异性(melanocyte-lineage-specific)TFs；mesenchymal-like状态下，JUN, SOX9
技术资料